An interventional study of Intermittent theta burst stimulation (iTBS) and Sham Intermittent theta burst stimulation (iTBS) in Multiple Sclerosis and Cognitive Impairment, sponsored by University of Nottingham. Status unknown at 1 site in United Kingdom. Open to participants aged 18 Years to 69 Years. Per ClinicalTrials.gov, last updated 2023-06-12.
Sponsored by University of Nottingham · Not applicable, Interventional, and Other
Cognitive difficulties can affect many people who live with multiple sclerosis (MS). These difficulties, such as within thinking, memory, and problem solving, can have an impact on important aspects of an individual's life, including their daily activities, work, and how they manage their condition. Previous studies have suggested that cognitive difficulties affect approximately 40-70% of people living with MS, yet there are currently no treatments to target these problems. Recent research has directed towards a non-invasive intervention which stimulates a part of the brain (called the dorsolateral prefrontal cortex, or DLPFC for short) which is reported to participate in cognitive processes, such as memory, thinking, and attention. This intervention, called "intermittent theta burst stimulation" (iTBS), involves placing a magnetic device to the skull to activate the DLPFC underneath. This technique has been used successfully in the treatment of depression and is widely considered safe and painless. Previous studies have also shown that iTBS intervention can lead to improvements in cognitive processes.
Before the investigators can progress to a large trial to explore its clinical effectiveness for reducing cognitive problems for people with MS, some aspects regarding its feasibility need to be clarified, for example whether it is an acceptable and tolerable intervention for people living with MS. A single-centre, mixed methods feasibility randomised controlled trial will be conducted to compare four groups (10 participants each) of iTBS administration. At baseline, End of Intervention (EOI), and 8-week follow up, the investigators will complete outcome measures to evaluate cognition, mood and fatigue. Participants will also undergo MRI scans at baseline and EOI. Following participation, participants will be interviews and the investigators will organise a post-participation workshop to explore their experiences of the trial, including the tolerability of the protocol and acceptability of the visit schedule, and any differences in cognition.
The primary objective is to assess the feasibility of the trial procedures, in terms of their acceptability and tolerability for pwMS who have cognitive impairment. For this aim, the completion of the intervention schedule will be measured (e.g., attending all sessions per the protocol, considering any missed appointments and reasons for non-attendance where possible) including the end of intervention assessments, as well as the 8-week follow up to ascertain participant willingness to complete the full study.
Participants will be randomly allocated to one of four groups (Group 1: 4 administrations of intermittent theta burst stimulation (iTBS) over 1 week; Group 2: 8 administrations of iTBS over 2 weeks; Group 3: 16 administrations of iTBS over 4 weeks; Group 4: 8 administrations of sham iTBS over 2 weeks). Participants will not be aware whether they have been allocated to receive active or sham iTBS administration.
Intervention - Active iTBS: Active connectivity-guided iTBS will be administered to the left dorsolateral prefrontal cortex (DLPFC). The administration comprises bursts of 3 pulses at 50Hz with a power of 80% motor threshold, at a burst frequency of 5 Hz (i.e., every 200ms) for 2 seconds, repeated every 10 seconds for a total of 190 seconds (600 pulses). Blocks are repeated a total of 3 times, with 5 minutes rest intervals between blocks. (Duration and frequency: 30 min, 4 times a week for up to 4 weeks depending on group).
Sham iTBS: The sham iTBS administration is performed under the same conditions and with an identical protocol and equipment to the full administration, except that it uses a commercially available sham iTBS coil designed for use in double-blind trials. This sham coil looks like the real coil and connects to the iTBS unit but delivers only a very weak and shallow stimulation thus simulating the sounds made by the real iTBS coil.
At baseline, End of Intervention (EOI), and 8-week follow up, outcome measures will be completed to evaluate cognition, mood and fatigue. Participants will also undergo MRI scans at baseline and EOI. The purpose of the MRI is to allow identification of the exact location over which the iTBS intervention will be applied, and it will allow measurement of brain function before iTBS intervention (or sham).
The MRI scan will include:
The investigators have developed a questionnaire to explore tolerability and acceptability of the procedures, and participants will also be invited to discuss their experience of participating in the trial at interview 8 weeks post-intervention.
Finally, at the end of the study, the investigators aim to host a post-participation workshop at the beginning of month 28, following collection and analysis of main outcomes. Depending on covid-safe recommendations from the government and university, this may be via video call or at a venue. All participants will be invited to discuss whether the experience of participation (varying from 1-week to 4-weeks) can inform which of intervention regime investigators should take forward into a subsequent pilot trial, to expand on the preliminary data analysis from the qualitative interviews. Investigators will explore the magnitude and nature of the effect on cognition that would be needed to be achieved to give a meaningful change to them personally, such that the iTBS interventions of different durations would be warranted. For example, participants may feel that only a major improvement in day-to-day cognition would justify a 4-week intervention, whereas others may feel that any benefit would justify this. These issues will be explored to inform future trial design.
3,524 studies on the registry are indexed under Multiple Sclerosis; 668 are open to participants now.
This study's planned enrollment of 40 is below the median of 50 across 2,386 interventional studies indexed under Multiple Sclerosis.
Browse Multiple Sclerosis studies →University of Nottingham is the lead sponsor of 463 studies on the registry; 78 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
iTBS intervention lasting 30 minutes, given 4 days a week, for 1 week
Other: Intermittent theta burst stimulation (iTBS)
iTBS intervention lasting 30 minutes, given 4 days a week, for 2 weeks
Other: Intermittent theta burst stimulation (iTBS)
iTBS intervention lasting 30 minutes, given 4 days a week, for 4 weeks
Other: Intermittent theta burst stimulation (iTBS)
Sham iTBS intervention lasting 30 minutes, given 4 days a week, for 2 weeks.
Other: Sham Intermittent theta burst stimulation (iTBS)
The localisation of the left dorsolateral prefrontal cortex (DLPFC) target will be identified using effective connectivity of the left caudate to identify the maximally-connected locus in the left DLFPC. Following this the iTBS will be administered to the target coordinates identified using the neuronavigation software available with the system. Connectivity-guided iTBS is then administered using a 70mm Double Air Film Coil (Magstim, Whitland, Dyfed, UK), connected to a Magstim Super Rapid-2 Plus-1 stimulator. The administration comprises bursts of 3 pulses at 50Hz with a power of 80% motor threshold at a burst frequency of 5 Hz (i.e., every 200ms) for 2 seconds, repeated every 10 seconds for a total of 190 seconds (600 pulses). Blocks are repeated a total of 3 times, with 5-minute rest intervals between blocks. During left DLPFC stimulation, the TBS coil is held by a support tangentially to the skull, with the axis of the coil angled approximately 90 degrees from the midsagittal axis.
The sham iTBS administration is performed under the same conditions and with an identical protocol and equipment to the full administration, except that it uses a commercially available sham iTBS coil designed for use in double-blind trials. This sham coil looks like the real coil and connects to the iTBS unit but delivers only a very weak and shallow stimulation thus simulating the sounds made by the real iTBS coil.
Feasibility of Trial Procedures
Number of sessions attended according to the protocol Number of missed/rescheduled appointments Reasons for non-attendance Completion of end of intervention assessments Completion of 8 weeks follow up assessments
Time frame: 8 weeks
Feasibility of recruitment
Proportion of eligible and consenting participants
Time frame: 1 week
The Brief Visuospatial Memory Test Revised (BVMT-R) Trials 1-3.
Raw scores range from 0 to 12 for each trial and reflect accuracy and correct placement (higher scores indicate better outcome)
Time frame: 8 weeks
The Brief Visuospatial Memory Test Revised (BVMT-R) Total learning
Sum of scores across the three trials (min: 0, max: 36; higher scores indicate better outcome).
Time frame: 8 weeks
The Brief Visuospatial Memory Test Revised (BVMT-R) Learning
The best of Trial 2 or 3 minus the Trial 1 score (min 0 max 23, higher scores indicate better outcome)
Time frame: 8 weeks
The Brief Visuospatial Memory Test Revised (BVMT-R) Delayed recall
Raw scores range from 0 to 12 (max) and reflect recall of designs after 25-min delay. Higher scores indicate better outcome.
Time frame: 8 weeks
The Brief Visuospatial Memory Test Revised (BVMT-R) Percent retained
Scores range from 1 to 100 (max) and reflect the amount originally learned that was retained across the delay. Higher scores indicate better outcome.
Time frame: 8 weeks
The Brief Visuospatial Memory Test Revised (BVMT-R) Recognition hits
\- Number of target figures correctly recognized; scores range from 0 to 6 (max). Higher scores indicate better outcome.
Time frame: 8 weeks
The Brief Visuospatial Memory Test Revised (BVMT-R) Recognition false alarms
Number of distractors incorrectly recognized as targets; scores range from 0 to 6 (max). Higher scores indicate better outcome.
Time frame: 8 weeks
The Brief Visuospatial Memory Test Revised (BVMT-R) Recognition discrimination index
Recognition hits minus recognition false alarms; scores range from -6 to 6 (max). Higher scores indicate better outcome.
Time frame: 8 weeks
The Brief Visuospatial Memory Test Revised (BVMT-R) Recognition response bias
Scores range from 0.00 to 1.00 (max) and reflect the tendency (or lack of) to answer "yes" to a recognition item. Higher scores indicate better outcome.
Time frame: 8 weeks
The California Verbal Learning Test-II (CVLT-II)
A computer administration and scoring system generates score, graphs a learning curve, and provides learning parameters, response errors and interference effects. Higher scores indicate better outcome.
Time frame: 8 weeks
The Symbol Digit Modalities Test (SDMT)
Raw score of correct items named per 90 seconds. Minimum value: 0 Maximum value: 130. Higher scores indicate better outcome.
Time frame: 8 weeks
Digit Span Forwards (from WAIS-IV)
Raw score, minimum 0, maximum 16. Higher scores indicate better outcome.
Time frame: 8 weeks
Digit Span Backwards (from WAIS-IV)
Raw score, minimum 0, maximum 16. Higher scores indicate better outcome.
Time frame: 8 weeks
Patient Health Questionnaire - Depression
Self-rated mood. Raw score, minimum 0, maximum 27. Lower scores indicate better outcome.
Time frame: 8 weeks
General Anxiety Disorder Scale
Self-rated anxiety. Raw score, minimum 0, maximum 21. Lower scores indicate better outcome.
Time frame: 8 weeks
Perceived Deficits Questionnaire (PDQ)
Self-reported cognitive impairment. Raw score, minimum 0, maximum 80. Lower scores indicate better outcome.
Time frame: 8 weeks
The Modified Fatigue Impact Scale (MFIS)
Self-reported fatigue. Raw score, minimum 0, maximum 84. Lower scores indicate better outcome.
Time frame: 8 weeks
The Edinburgh Handedness Inventory (EHI)
Self-rated handedness to determine whether one favours left or right-handedness. It is not scored; result will be binary (left/right).
Time frame: 1 week
Change in effective connectivity between left dorsolateral prefrontal cortex and left caudate nucleus
As above
Time frame: 5 weeks
Change in cerebral blood flow in the left dorsolateral prefrontal cortex and in the left caudate nucleus (normalised to whole brain cerebral blood flow)
As above
Time frame: 5 weeks
Safety outcomes of iTBS
Number of participants with treatment-related adverse events and number of events each, as reported to research team
Time frame: 4 weeks
Undesired effects of iTBS
Number of participants with self reported negative effects e.g., headaches, dizziness
Time frame: 4 weeks
iTBS Experience Questionnaire - Tolerability
Unpleasant sensations of iTBS. Minimum score 0, maximum score 15. Higher indicates worse outcome.
Time frame: 1 week
iTBS Experience Questionnaire - Acceptability
Minimum score 0, maximum score 30. Higher score indicates better outcome.
Time frame: 1 week
iTBS Experience Questionnaire - Blinding
Number of participants who correctly guessed allocation to sham/active iTBS intervention
Time frame: 1 week
Interviews - Tolerability
Tolerability of the trial procedures - qualitative analysis via framework method
Time frame: 1 week
Interviews - Acceptability
Acceptability of the trial procedures of the trial procedures- qualitative analysis via framework method
Time frame: 1 week
Interviews - perceived differences
Subjective perceived differences in cognitive abilities in daily life - qualitative analysis via framework method
Time frame: 1 week
Interviews - Improvements
Suggested improvements to refine trial procedures - qualitative analysis via framework method
Time frame: 1 week
Post-participation workshop
A semi-structured focus group schedule will explore qualitative data regarding meaningful changes to cognition/mood and how much change would be expected given the requirements of the intervention at the post-participation workshop. This will be analysed using framework analysis.
Time frame: 1 week
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jun 2022 (actual). Primary completion is estimated for Aug 2023, 14 months after the start.
Of 868 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 14 months is below that.
Counting every sponsor, half of 889 studies reached it within 21 months; a quarter within 9 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.